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suspected. Patients and Methods: Six male and 2 female patients
with hematologic malignancies, median age 45 (22-55) years, re-
ceiving unrelated stem cell transplants in our institution within the
last 6 years, experienced primary (n 5) or secondary (n 3) graft
failure. Match was 7/8 in one, 8/8 in three, 8/10 in three and 9/10
in one case. Primary conditioning was myeloablative in all patients
and included rabbit ATG either Genzyme or Fresenius in all but
one. Graft source was bone marrow in 7 and PBSC in one case,
respectively. Mechanism of graft failure was evaluated by morphol-
ogy, immunophenotyping, chimerism and kinetics and was judged
rejection in three and probably immunologically mediated in 5
cases. At a median of 42 (35-71) days following the ﬁrst transplant
7 patients received PBSC and one patient bone marrow as a second
transplant, 4 from the same and 4 from a different unrelated donor.
Matches of the new donors were 6/8, 7/8, 8/10 and 10/10. Two
earlier patients were given ﬂudarabin 100 and 120 mg/m2 com-
bined with ATG Genzyme 5 mg/kg BW, the later ones ﬂudarabin
150 mg/m2 together with ATG 7.5 mg/kg BW. Results: Seven out
of 8 patients engrafted at a median of 14 days after second and 58
days after ﬁrst transplant. One non-engraftment occurred in a
polytransfused patient with refractory anemia and primary rejec-
tion, after reconditioning with ﬂudarabin 100 mg/m2 and ATG 5
mg/kg BW and grafting with the same donor. At a median obser-
vation time of 555 (266-2020) days 4 patients are alive and well.
Four patients died at a median of 135 (75-337) days: two from
relapse, one from aGvHD °IV and one from fungal sepsis. Con-
clusion: In primary and secondary graft failure after allogeneic
stem cell transplantation, for reconditioning a highly immunosup-
pressive regimen with limited toxicity is warranted. Fludarabin 150
mg/m2 and ATG Genzyme 7.5 mg/kg BW is a very efﬁcient and
well tolerated combination enabling engraftment even across a two
HLA antigen barrier.
61
COSTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION
Svahn, B.-M.B.M.S.1,2, Alvin, O.O.A.3, Ringden, O.O.R.1,2,
Gardulf, A.A.G.2, Remberger, M.M.R.2 1Center for Allogeneic Stem
Cell Transplantation, Karolinska University Hospital/Huddinge, Stock-
holm, Sweden; 2Department of Laboratory Medicine, Division of Clinical
Immunology, Karolinska Institutet, Stockholm, Sweden; 3Department of
Internal Auditing, Karolinska Institutet, Stockholm, Sweden.
Purpose: To determine the total costs after allogeneic hemato-
poietic stem cell transplantation (ASCT) and the pre- and post-
transplant conditions or factors associated with increases or de-
creases in costs. Patients and Methods: We collected all in- and
outpatient costs during ﬁve years in 93 patients who had under-
gone ASCT in 1998 and 1999 at Huddinge University Hospital in
Stockholm, Sweden. The inpatient costs included all those related
to a patient from the ﬁrst day of admission until discharge and then
all costs of readmission to any hospital in the Stockholm area.
Results: The total median cost of ﬁve posttransplant years was
163675.61 (61160.87-405790.22) USD. The costs were highest
during the ﬁrst year—i.e., median inpatient and outpatient costs
118165.68 USD and 15339.82 USD, respectively. The total costs
during the ﬁrst year were higher in patients with acute graft-
versus-host disease grades III-IV (relative hazards [RH] 1.35, P 
.003), bacteremia (RH 1.33, P  .005), veno-occlusive disease of
the liver (RH 1.32, P .005), prophylaxis with granulocyte colony-
stimulating factor (G-CSF; RH 1.31, P .01), acute leukemia (RH
1.32, P  .008) and treatment in hospital instead of at home (RH
1.20, P  .07). During the early transplant period, a second
transplantation (RH 1.35, P .004) and hemorrhagic cystitis (HC)
(RH 1.24, P  .03) were also associated with higher costs. The
total ﬁve-year cost declined with longer survival rates (r  0.4028,
P  .001) and reduced intensity conditioning (RH 0.79, P  .024).
Conclusion: Higher costs of ASCT were associated with retrans-
plantation, acute leukemia, G-CSF prophylaxis, hospital care, my-
eloablative conditioning and major transplant-related complica-
tions.
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HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) USING FLU-
DARABINE, BUSULFAN AND THYMOGLOBULIN: A MATCHED COMPAR-
ISON TO HCT WITH BUSULFAN AND CYCLOPHOSPHAMIDE
Bredeson, C.1,2, Kurian, S.1, Zhang, M.-J.1, Muehlenbein, C.1,
Nugent, M.1, Brown, C.3, Stewart, D.3, Savoie, L.3, Bahlis, N.3,
Chaudhry, A.3, Quinlan, D.3, Russell, J.3, Horowitz, M.M.1 1The
Center for International Blood and Marrow Transplant Research, Med-
ical College of Wisconsin, Milwaukee, WI; 2Cancer Care Manitoba,
Winnipeg, MB, Canada; 3The Alberta Blood and Marrow Transplant
Program, Foothills Hospital and Tom Baker Cancer Center, Calgary,
AB, Canada.
Allogeneic HCT after standard myeloablative conditioning is
associated with signiﬁcant risks of regimen related mortality and
graft versus host disease (GVHD). Over the past 5 years, a novel
ﬂudarabine-based conditioning regimen using a low dose of rabbit
ATG (Thymoglobulin) with ﬂudarabine and intravenous busulfan
has been used at The Alberta Blood and Marrow Transplant
Program in Calgary. Initial data suggest a lower incidence of acute
GvHD with this approach in a diverse population of patients with
acute leukemia (n  48), chronic myelogenous leukemia (n  21),
chronic lymphocytic leukemia (n  9), myelodysplasia (n  22),
lymphoma (n  23) and multiple myeloma (n  11). To assess
further this single center experience, we performed a retrospective
analysis comparing their outcomes with matched controls receiv-
ing HCT after conditioning with standard busulfan and cyclophos-
phamide during the same time period. We attempted to select two
controls for each case from 574 eligible patients reported to the
CIBMTR. All patients were 18 to 65 years of age, received HLA-
identical sibling peripheral blood or bone marrow transplants for
the diseases noted above from 1999-2003 and were given cyclo-
sporine and methotrexate for GVHD prophylaxis. Controls were
selected to match on disease and disease status at transplant and to
minimize age differences. Two matches were found for 95 cases, 1
for 26 and none for 13. The latter 13 were excluded from further
study leaving 121 cases and 216 matched controls available for
comparison. Median follow-up was 30 (range, 12-61) months for
cases and 35 (range, 2-72) months for controls (P  .47). Com-
pared to the 216 controls, the 121 cases had lower Karnofsky scores
before transplant, and were more likely to receive a peripheral
blood transplant. Outcome comparisons used multivariate Cox
regression, stratiﬁed on the matched pair, to adjust for these
differences. The risk of grades II-IV acute GvHD (relative risk
[RR] 0.34, 95% conﬁdence interval [CI], 0.20-0.59, P .0001) and
overall mortality (RR 0.48, CI, 0.29-0.77, P  .003) were signiﬁ-
cantly lower in cases versus controls. The risk of chronic GvHD
was similar in the cases and controls. These results suggest that the
novel regimen ﬂudarabine, busulfan and Thymoglobulin decreases
the risk of acute GvHD and improves survival after HLA-identical
sibling HCT and support the development of a prospective multi-
center randomized clinical trial to conﬁrm these ﬁndings.
63
LOW TREATMENT RELATED MORTALITY AND IMPROVED SURVIVAL IN
ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANT: TAR-
GETED INTRAVENOUS BUSULFAN COMBINED WITH FLUDARABINE
(tBuFlu) AS CONDITIONING REGIMEN
Field, T.L., Perkins, J., Alsina, M., Ayala, E., Fancher, K., Janssen, W.,
Perez, L., Sullivan, D., Tate, C., Anasetti, C. H. Lee Mofﬁtt Cancer
Institute, Tampa, FL.
Myeloablative doses of intravenous busulfan in combination with
ﬂudarabine have been employed as conditioning before hemato-
poietic cell allografts with reduced treatment-related toxicity and
mortality. In this report, we describe the early results of a targeted
busulfan pharmacokinetic dosing strategy (tBuFlu) used in combi-
nation with ﬂudarabine before either related or unrelated grafts
We treated 61 pts with tBuFlu prior to allogeneic peripheral blood
stem cell transplantation. The median patient age was 48 (range
22-68) years. Patient diagnoses included AML (13 de novo, 7 with
prior MDS, and 7 treatment related), MDS (7 pts), MF (5), NHL
(6 pts), ALL (6 pts), CML (5 pts), CLL (2), MM (2) and PNH (1).
Five patients had received a prior autologous HCT. Donors were
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HLA-A, B, C, DRB1, DQB1 matched siblings (29), matched
unrelated donors (22), or unrelated donors mismatched for one
HLA antigen (6), homozygous mismatch (1), one HLA allele (2),
or two HLA alleles (1). Fludarabine 40 mg/m2 was given intra-
venously daily for four days, with each infusion followed imme-
diately by intravenous busulfan. The dose of busulfan for days 1
and 2 was 130 mg/m2. Pharmacokinetic analysis was performed
after the ﬁrst infusion of busulfan; in 59 pts, the goal was to
adjust busulfan doses for days 3 and 4 to achieve an average
targeted Css level of 800-1000 ng/ml. Levels were drawn incor-
rectly in 4 of these pts and doses were not changed. Thirty-ﬁve
(59%) pts had their doses adjusted, increased in 27 and de-
creased in 8, while 20 pts had Css within the desired range
without adjustment. Patients received tacrolimus and standard
doses of methotrexate for GVHD prophylaxis, with the excep-
tion of ﬁve patients. Engraftment occurred in 58 (95%) pts.
Thirty (64%) of 47 pts followed for at least 100 days experi-
enced acute GVHD requiring treatment. Six pts have died of
transplant-related complications and 7 pts have failed to achieve
remission or have relapsed. Median follow-up is 174 days (range
26-448 days). The 100-day K-M estimate of survival for the
whole cohort is 92%, and event-free survival 88%. The 100-day
mortality in this study compares well with the 100-day mortality
reported to the IBMTR for patients with AML, ALL, MDS, and
CML transplanted from either HLA-matched siblings or unre-
lated donors. These preliminary results indicate that tBuFlu is a
promising myeloablative regimen that can be utilized in older
patients with low early treatment-related mortality.
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LACK OF IMMUNE BARRIER TO ALLOGENEIC HEMATOPOIETIC STEM CELL
ENGRAFTMENT IN T, B, AND NK CELL DEFICIENT (RAG2C/B6) MICE
Logronio, K.A.1, Burge, M.2, Shizuru, J.3 1Division of Bone Marrow
Transplant, Stanford University School of Medicine, Palo Alto, CA.
The way that allogeneic hematopoietic stem cells (HSC) resist
engraftment is not completely understood. Natural killer cells
(NK) and lymphocytes are thought to mediate the allograft barrier
in mice that are mismatched at the major histocompatibility com-
plex (MHC). The clearing of niche space is also thought to be
required for donor cell engraftment. Here we attempt to dissect
the relative contribution of these host elements to hematopoietic
resistance using genetically defective Rag2/ (H2b) mice lacking
T and B cells, or Rag2c/ (H2b) mice lacking in T, B, and NK
cells as recipients. We have previously shown that HSCs encounter
greater resistance to engraftment when compared to unfraction-
ated bone marrow (BM), and the resistance can be quantitated by
titrating numbers of HSCs needed to rescue lethally irradiated
recipients. Rescue of syngeneic or CD45 congenic recipients re-
quires only 200 HSCs, whereas higher HSC doses are required as
the genetic disparity increases. In this study, radioresistant MHC-
mismatched AKR/J (H2k) HSCs were transplanted into lethally
irradiated (950 cGy) B6.WT (H2b). All B6.WT mice died of
hematopoietic failure despite attempted rescue with 1000 AKR/J
HSC. No signiﬁcant improvement in engraftment was observed in
Rag2/ mice when compared to B6.WT mice. However, an
impressive difference was noted in the Rag2c/ mice, in which
the immune barrier completely disappeared. A dose of 300 HSC
rescued all irradiated Rag2c/ mice and even 200 AKR HSC, an
amount equivalent to a congenic dose rescued 100% of recipients.
We then sought to determine if engraftment could be achieved
using non-myeloablative conditioning, or no radiation at all.
Rag2c/ recipients of 6000 AKR/J HSCs treated with 500 cGy-
300 cGy resulted in 100% donor engraftment. Additionally, un-
conditioned Rag2c/ also engrafted since 10-20% of donor
AKR/J granulocytes were detected. In contrast, unconditioned
Rag2/ mice showed no evidence of donor cell engraftment. We
also studied the trafﬁcking of allogeneic FVB (H-2q) HSC in
irradiated versus unirradiated Rag2c/ (H-2d) recipients by in
vivo bioluminescence imaging. HSC were observed to enter the
marrow space of irradiated mice within minutes following infusion,
whereas unirradiated mice demonstrated no luciferase signal until
day 5 post-infusion. We conclude that Rag2c/ mice have a
profound reduction in the immune barrier to allogeneic HSC
engraftment and, that in irradiated mice, HSC rapidly enter the
marrow.
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POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (Cy) AS A SINGLE
AGENT FOR GVHD PROPHYLAXIS AFTER HLA MATCHED RELATED AND
UNRELATED BONE MARROW TRANSPLANTATION
Luznik, L., Chen, A., Fuchs, E.J., Phelps, M., Crawford, A.,
Brodsky, R.A., Huff, C.A., Jones, R.J. Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins, Baltimore, MD.
In animal models of BMT, a properly timed high dose of Cy
post-BMT selectively eliminates host-versus-graft and graft-ver-
sus-host reactive T cells, thereby preventing graft rejection and
reducing GVHD. We hypothesized that high dose posttransplant
Cy (50 mg/kg IV) administered on days 3 and 4 after BuCy
conditioning may be effective in preventing GVHD and can limit,
or entirely eliminate the need for, standard postgrafting immuno-
suppression. This should lessen immunosuppression and allow
early institution of additional posttransplant immunotherapy such
as DLI. 28 patients with advanced hematologic malignancies were
conditioned with busulfan (PO or IV) on days 7 to 3 and Cy on
days 2 and 1, transplanted with non–T cell–depleted marrow,
and treated with Cy on days 3 and 4 as only postgrafting
immunosuppression. 15 patients (median age 41 years) were al-
lografted with bone marrow from HLA-identical siblings. Time to
neutrophil (	500/l) and platelet (	20000/l, untransfused) en-
graftment was 22 and 31 days, respectively. One patient experi-
enced secondary graft failure and was successfully rescued. Acute
GVHD occurred in 7/15 patients at a median of 43 days after
transplantation (range 20-68 days) and was exclusively grades I (2
patients) and II (5 patients). All 7 patients with GVHD responded
completely to standard therapy (steroids only or steroids  FK-
506) and all of them were successfully rapidly weaned from all
immunosuppressive agents. With a median follow-up of 290 days
(range 50-380), 10/15 patients are alive (all 5 patients died of
relapsed disease) of which 7 are in remission. 13 patients (median
age 41 years) received bone marrow from HLA-matched unrelated
donors. Primary graft failure occurred in 2 recipients of unrelated
marrow, and was fatal in one. One patient died from VOD. Time
to neutrophil and platelet engraftment was 25 and 71 days, respec-
tively. Of the 11 patients that engrafted, 1 developed grade I, 4
developed grade II and 1 developed grade III acute GVHD. All of
them rapidly responded to standard therapy. From an overall
survival perspective, 10/13 patients are alive of which 6 are in
remission, with a median follow-up of 290 days (range 75-430).
This preliminary analysis suggests that high dose post-transplan-
tation Cy is effective as a single agent in the prophylaxis of severe
GVHD after myeloablative conditioning and HLA-matched re-
lated BMT and should be studied in patients with standard risk
hematologic malignancies.
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OUTCOME OF ALTERNATIVE DONOR TRANSPLANTATION FOR SEVERE
APLASTIC ANEMIA CAN BE COMPARABLE TO OUTCOME WITH
MATCHED RELATED DONORS
Kennedy-Nasser, A.A., Leung, K., Gottschalk, S., Lee, D.A.,
Carrum, G., Heslop, H.E., Brenner, M.K., Bollard, C.M., Krance, R.A.
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas
Children’s Hospital, The Methodist Hospital, Houston, TX.
Matched related donor (MRD) bone marrow transplantation is
the treatment of choice for pediatric patients with severe aplastic
anemia (SAA); however, only 25% of patients will have an HLA-
identical sibling. Alternative donor transplants may be an option
for these patients, but such therapies have been associated with
greater incidences of graft failures and graft-versus-host disease
(GVHD). We retrospectively analyzed 32 pediatric patients who
have undergone 34 hematopoietic stem cell transplants for severe
aplastic anemia at our institution from April 1997 to April 2005.
One patient had a MRD transplant followed by a matched unre-
lated donor (MUD) transplant, while another had an HLA-mis-
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